Phase II Trial of Front-Line Brentuximab Vedotin for Patients Aged ≥60 Years with Hodgkin Lymphoma


Phase II Trial of Front-Line Brentuximab Vedotin for Patients Aged ≥60 Years with Hodgkin Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Yasenchak C et al. A Phase 2 study of single-agent brentuximab vedotin for front-line therapy of Hodgkin lymphoma in patients age 60 years and above: Interim results. Proc ASH 2013;Abstract 4389.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts University School of Medicine and Director of the Lymphoma Program and Leader of the Clinical Sciences Program at Tufts Cancer Center in Boston, Massachusetts.